Blog
RSS FeedPosted by Michael Wonder on 14 Jul 2020
Alnylam announces that the United Kingdom’s MHRA grants early access to lumasiran
13 July 2020 - Positive scientific opinion under Early Access to Medicines Scheme will make lumasiran treatment available for UK primary ...
Posted by Michael Wonder on 13 Jul 2020
Six months into the pandemic, how much closer are we to a vaccine?
13 July 2020 - Queensland scientists racing to make a COVID-19 vaccine are upbeat as their research begins critical human ...
Posted by Michael Wonder on 13 Jul 2020
Are high‐cost drug funding mechanisms fit for purpose? A retrospective study of individual funding requests in an NHS tertiary hospital
13 July 2020 - This paper reports on a retrospective study of individual funding request submissions from a large tertiary hospital ...
Posted by Michael Wonder on 10 Jul 2020
Collaborative consultation on medicines policy closes
10 July 2020 - Over the past few months, Medicines New Zealand ran an online consultation on a discussion paper produced ...
Posted by Michael Wonder on 09 Jul 2020
Drugmakers appeal limited insurance benefit for dementia drug choline alfoscerate
9 July 2020 - Sixty-six manufacturers of choline alfoscerate, a dementia drug, filed an appeal to the Health Insurance Review ...
Posted by Michael Wonder on 09 Jul 2020
'Xolair’s reimbursement will change treatment paradigm for asthma patients'
9 July 2020 - Novartis Korea will be able to strengthen its position in the severe allergic asthma market with ...
Posted by Michael Wonder on 08 Jul 2020
So just who do we think qualifies for any COVID-19 vaccine?
9 July 2020 - How should we allocate scarce medical resources? ...
Posted by Michael Wonder on 06 Jul 2020
Access to HIV medicines severely impacted by COVID-19 as AIDS response stalls
6 July 2020 - Countries seek innovative ways to mitigate the impact of disruptions and keep services going. ...
Posted by Michael Wonder on 06 Jul 2020
Canadians demand access to ‘miracle’ cystic fibrosis drug already approved in U.S. and U.K
6 July 2020 - Montreal’s Chelsea Gagnon may look like a healthy 31-year-old woman at first glance, but every single ...
Posted by Michael Wonder on 06 Jul 2020
Better protection against meningococcal and pneumococcal diseases
6 July 2020 - The National Immunisation Program has been amended from 1 July 2020 to improve protection for those most ...
Posted by Michael Wonder on 05 Jul 2020
Britain nears $625 million Sanofi/GSK COVID-19 vaccine deal
5 July 2020 - Britain is close to a 500 million pound ($624 million) supply deal with Sanofi and GlaxoSmithKline for ...
Posted by Michael Wonder on 05 Jul 2020
FDA Commissioner says he can't predict when vaccine will be ready after Trump's timeline claims
5 July 2020 - Food and Drug Administration Commissioner Stephen Hahn said Sunday that he would not make a prediction ...
Posted by Michael Wonder on 05 Jul 2020
Clock ticking on Edmonton family's hope for $2.8 million drug treatment for toddler son
3 July 2020 - Family hoping Alberta Health will pay for new drug that must be administered by mid-July. ...
Posted by Michael Wonder on 02 Jul 2020
Vertex announces expansion of reimbursement agreement with NHS England to include Kaftrio (ivacaftor/tezacaftor/elexacaftor) in combination with Kalydeco (ivacaftor)
30 June 2020 - Cystic fibrosis patients in England will be among the first in Europe to benefit from access to ...
Posted by Michael Wonder on 01 Jul 2020
Why States’ ‘Netflix model’ prescription drug arrangements are no silver bullet
1 July 2020 - In June 2019, Louisiana contracted with Asegua Therapeutics––a subsidiary of Gilead Sciences––to pay a lump sum ...